Journal of clinical virology plus最新文献

{"title":"Systemic reactogenicity is a correlate of MF59 adjuvant-moderated immunogenicity in influenza vaccinated children","authors":"Charlotte Switzer ,&nbsp;Chris P. Verschoor ,&nbsp;Eleanor Pullenayegum ,&nbsp;Pardeep Singh ,&nbsp;Mark Loeb","doi":"10.1016/j.jcvp.2025.100234","DOIUrl":"10.1016/j.jcvp.2025.100234","url":null,"abstract":"<div><h3>Background</h3><div>Adjuvanted influenza vaccine induces more robust antibody responses, but is associated with more adverse events following vaccination. Prior work has examined the link between vaccine reactions and immunogenicity in adults, but little is known about the association between reactogenicity and postvaccination antibody responses in children, particularly regarding adjuvanted influenza vaccine. This study examines the relationship between reactogenicity and immunogenicity in children vaccinated against influenza, and the immunomodulatory effects of the adjuvant.</div></div><div><h3>Methods</h3><div>We conducted a secondary analysis of data from a cluster-randomized trial of children aged 6 to 72 months from Canadian Hutterite colonies. Participants received either a trivalent MF59-adjuvanted vaccine (aTIV) or a quadrivalent non-adjuvanted vaccine (QIV). Reactogenicity was measured using a composite score based on local, systemic, and respiratory reactions recorded within five days post-vaccination. Immunogenicity was assessed by measuring hemagglutination inhibition (HAI) titers before and four weeks after vaccination. Linear mixed models were used to evaluate associations between reactogenicity scores and post-vaccination log-transformed HAI titers.</div></div><div><h3>Results</h3><div>In adjuvanted vaccinees, higher systemic reactogenicity scores were associated with increased antibody titers for A/H1N1 and B/Victoria, relative to nonadjuvanted vaccinees (β: 0.38, 95 % CI: 0.17 to 0.60; and (β: 0.44, 95 % CI: 0.24 to 0.64 respectively). Higher systemic reactogenicity in nonadjuvanted vaccinees correlated with reduced post-vaccination antibody titers for A/H1N1 (β:0.36, 95 % CI:0.54 to -0.18) and B/Victoria (β:0.37, 95 % CI:0.54 to -0.20). Respiratory reactogenicity was positively correlated with immunogenicity in responses to A/H3N2 in the adjuvanted group (β: 0.78, 95 % CI: 0.13 to 1.43). Local reactogenicity was associated with A/H1N1 immunogenicity, but showed no significant interaction with vaccine formulation (β: 0.25, 95 % CI: 0.04 to 0.47).</div></div><div><h3>Conclusions</h3><div>Systemic reactogenicity in adjuvanted vaccinees showed positive correlations with immunogenicity, whereas reactogenicity contributed to blunting of antibody responses in nonadjuvanted vaccinees. We found that stronger systemic reactions correlate with improved immune responses in the adjuvanted group against all vaccine strains save A/H3N2, which warrants further investigation. Our study finds that reactogenicity is a modest biomarker for vaccine immunogenicity, and that the increased reactogenicity of the adjuvanted vaccine is associated with enhanced immune responsiveness, which may predict greater vaccine effectiveness.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 4","pages":"Article 100234"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145465301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The immunogenicity of recombinant zoster vaccination in patients with secondary immunodeficiencies: a literature review","authors":"Stascha I. Kuipers ,&nbsp;Marjolein Knoester ,&nbsp;Carin L.E. Hazenberg ,&nbsp;Debbie van Baarle ,&nbsp;Marieke van der Heiden","doi":"10.1016/j.jcvp.2025.100231","DOIUrl":"10.1016/j.jcvp.2025.100231","url":null,"abstract":"<div><div>Herpes zoster (HZ), caused by reactivation of the varicella zoster virus, is characterized by painful rashes and severe complications. Immunocompromised individuals are at greater risk of developing HZ. Vaccination with the novel recombinant adjuvanted zoster subunit vaccine (RZV) proved highly effective in older adults and is considered safe in patients with secondary immunodeficiencies. This review summarizes the current evidence on efficacy and immunogenicity of RZV in patients with secondary immunodeficiencies and identifies factors associated with reduced immunogenicity.</div><div>RZV is highly immunogenic in patients with HIV and most haematological malignancies. Reduced responsiveness has been observed in patients with solid tumours, chronic lymphocytic leukaemia, non-Hodgkin B-cell lymphoma, autologous haematopoietic cell transplants, and solid organ transplants. Reduced response is associated with Rituximab and post-transplantation immunosuppressive treatments, as well as immunosuppressive effects of solid tumours and chemotherapy. Future research should investigate whether personalised vaccination schedules, guided by biomarkers for immune function and treatment and/or transplantation schedules, may improve RZV responsiveness.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 4","pages":"Article 100231"},"PeriodicalIF":1.4,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145266557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance of dried blood spot sampling in quantifying hepatitis B DNA in Vietnam","authors":"Manh-Tuan Ha ,&nbsp;Duyen Thi-My Nguyen ,&nbsp;Tuan-Anh Nguyen","doi":"10.1016/j.jcvp.2025.100230","DOIUrl":"10.1016/j.jcvp.2025.100230","url":null,"abstract":"<div><h3>Background</h3><div>Sampling is a crucial step in quantifying HBV DNA. In some situations, dried blood spot (DBS) sampling is required. This study aimed to validate the accuracy of HBV DNA quantification from DBS samples and to evaluate the stability of HBV DNA levels under practical storage conditions.</div></div><div><h3>Materials and Methods</h3><div>We collected paired serum and DBS samples from HBV DNA-positive cases and HBV DNA-negative controls (1:1 ratio). The validity of DBS samples in HBV DNA quantification was determined using serum results as a gold standard.</div></div><div><h3>Results</h3><div>The study analyzed 100 paired DBS and serum samples from both cases and controls. It reported relatively high sensitivity (86.7%) and specificity (97.6%) for DBS samples in detecting HBV DNA levels greater than 2000 IU/mL. A strong linear regression correlation was found between HBV DNA levels in DBS and serum samples, with an R² of 0.8679 (p &lt; 0.001) and the regression equation y = 0.9095x - 0.7792. The mean difference in HBV DNA levels between DBS and serum was 1.28 ± 0.78 log10 IU/mL. Notably, differences in HBV DNA levels in DBS samples remained insignificant after 14 days of storage at both 4°C and room temperature (p&gt;0.05), indicating stability under various storage conditions.</div></div><div><h3>Conclusion</h3><div>This study demonstrates that DBS samples are effective for identifying patients eligible for treatment and remain stable at room temperature for at least 14 days, supporting their feasibility in real-world settings. The use of DBS samples for monitoring hepatitis B treatment response and optimizing the elution process presents promising research opportunities.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 4","pages":"Article 100230"},"PeriodicalIF":1.4,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145266558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of inflammatory markers including neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, mean platelet volume, platelet distribution width, and red blood cell distribution width in viral hepatitis: A systematic review and meta-analysis","authors":"Peyvand Parhizkar Roudsari ,&nbsp;Shayan Shojaei ,&nbsp;Parisa Firoozbakhsh ,&nbsp;Alireza Azarboo ,&nbsp;Saeed Mirmoosavi ,&nbsp;Ali Moradi ,&nbsp;Faeze Abbaspour ,&nbsp;Asma Mousavi ,&nbsp;Hanieh Radkhah","doi":"10.1016/j.jcvp.2025.100229","DOIUrl":"10.1016/j.jcvp.2025.100229","url":null,"abstract":"<div><h3>Background</h3><div>Hematological markers offer valuable and cost-effective tools for hepatitis prognosis and treatment customization due to their role in inflammatory responses. Hence, this study seeks to explore the prognostic potential of inflammatory markers including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), mean platelet volume (MPV), platelet distribution width (PDW), and red blood cell distribution width (RDW) in viral hepatitis patients.</div></div><div><h3>Methods</h3><div>We conducted a systematic search in online databases of PubMed, Web of Science, Scopus, and Cochrane for related articles following PRISMA guidelines. Our endpoint was to evaluate the association between NLR, PLR, MPV, PDW, and RDW with fibrosis and cirrhosis outcomes in patients with hepatitis B and C. The analysis used the \"meta\" package in R, employing Hedges' g to calculate the standardized mean difference (SMD) and 95 % confidence intervals (CI). A P value less than 0.05 was considered statistically significant for all data analyses</div></div><div><h3>Results</h3><div>Thirty-seven studies were ultimately included in the analysis. PLR was higher in mild fibrosis (SMD = -0.48, 95 % CI: -0.90; -0.06), with no significant differences observed by hepatitis type. Both MPV and RDW were higher in advanced fibrosis (MPV: SMD = 0.36, 95 % CI: 0.19; 0.53, RDW: SMD = 0.32, 95 % CI: 0.14; 0.50), and they were significantly increased in advanced hepatitis C fibrosis. PDW was higher in advanced fibrosis (SMD = 0.32, 95 % CI: 0.02; 0.61), significantly in hepatitis B. In cirrhotic versus non-cirrhotic patients, MPV (SMD = 0.22, 95 % CI: 0.07; 0.38) and RDW (SMD = 1.35, 95 % CI: 0.62; 2.08) were higher in the cirrhotic group, while PLR (SMD = -1.15, 95 % CI: -2.16; -0.15) was higher in the non-cirrhotic group. NLR showed no significant difference between mild and advanced fibrosis or between cirrhotic and non-cirrhotic groups.</div></div><div><h3>Conclusion</h3><div>This meta-analysis reveals the importance of hematological parameters of MPV, PDW, RDW, and PLR as predictors of viral hepatitis progression. MPV, PDW, and RDW are elevated in advanced fibrosis, while PLR is notably higher in mild fibrosis.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 4","pages":"Article 100229"},"PeriodicalIF":1.4,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144895302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"China reports first human case of Mpox: A call for global surveillance for public health and policy","authors":"Uthman Okikiola Adebayo ,&nbsp;Tolutope Adebimpe Oso ,&nbsp;Safayet Jamil ,&nbsp;Olalekan John Okesanya ,&nbsp;Mohamed Mustaf Ahmed","doi":"10.1016/j.jcvp.2025.100226","DOIUrl":"10.1016/j.jcvp.2025.100226","url":null,"abstract":"","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 3","pages":"Article 100226"},"PeriodicalIF":1.6,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144672278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance of an automated platform for CMV, EBV and BKPyV DNA detection and quantification","authors":"Yoann Fluhr ,&nbsp;Karine Saune ,&nbsp;Kevin Oliveira-Mendes ,&nbsp;Estelle Raguin ,&nbsp;Lila Poiteau ,&nbsp;Arnaud Del Bello ,&nbsp;Nassim Kamar ,&nbsp;Jacques Izopet ,&nbsp;Florence Abravanel","doi":"10.1016/j.jcvp.2025.100228","DOIUrl":"10.1016/j.jcvp.2025.100228","url":null,"abstract":"<div><div>Quantification of cytomegalovirus (CMV), Epstein-Barr virus (EBV), and BK polyomavirus (BKPyV) DNA is crucial for diagnosing related infections. The analytical performance of the Altostar® CMV, EBV and BKPyV DNA assays used in the AltoStar® AM16 instrument was assessed.</div><div>The Limit of detection was 215 international units/ml (IU/ml) for the CMV assay, 330 IU/ml for the EBV assay and 133 IU/ml for the BKPyV assay. A good concordance was found between the nominal value of the NIBSC standards and the AltoStar® results. Linearity was verified up to 5.7 log₁₀ IU/ml. Intra-assay and inter-assay reproducibility showed low disparity with a standard deviation &lt; 0.27 log₁₀ IU/ml.</div><div>The concordance with our previous DNA assays on clinical samples for CMV detection was 95.5% (<em>n</em> = 22), 90.6% for EBV (<em>n</em> = 32) and 92% for BKV (<em>n</em> = 25). The quantitative results were highly correlated.</div><div>The Altostar® platform provides accurate quantification for clinical monitoring of CMV, EBV and BKPyV DNA.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 3","pages":"Article 100228"},"PeriodicalIF":1.6,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144679836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dengue virus proteins: Dual drivers of pathogenesis and vaccine development","authors":"Haidar Ali ,&nbsp;Iffat Saleem ,&nbsp;Kashif Abdaal ,&nbsp;Mobeen Ur Rashid ,&nbsp;Imran Shahid ,&nbsp;Sadia Aziz ,&nbsp;Jing Yang ,&nbsp;Liaqat Ali","doi":"10.1016/j.jcvp.2025.100227","DOIUrl":"10.1016/j.jcvp.2025.100227","url":null,"abstract":"<div><div>This systematic review provides a comprehensive exploration of Dengue virus (DENV), focusing on its history, transmission dynamics, tropism, structural proteins, and potential vaccine development targets. Originating from sub-Saharan Africa, DENV has spread globally, facilitated by Aedes mosquitoes. The review highlights challenges posed by mosquito expansion and climate change on DENV transmission. It delves into DENV tropism, emphasizing interactions with immune cells and tissue-specific infection outcomes. Structural proteins, including Capsid, Pre-Membrane, and Envelope, are examined for their roles in viral assembly and maturation. Targeting strategies for structural proteins, particularly the Envelope protein domain III (EDIII), are discussed in the context of vaccine development. Additionally, non-structural proteins such as NS1, NS3, and NS5 are explored for their contributions to viral replication, host immune modulation and potential as both therapeutic targets and vaccine components. By integrating insights into both structural and non-structural elements of DENV, this review underscores the importance of a multifaceted approach to vaccine design and antiviral development aimed at effectively controlling dengue infection and its associated disease burden.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 3","pages":"Article 100227"},"PeriodicalIF":1.6,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144687298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency and clinical characteristics of human bocavirus in respiratory illnesses across diverse age groups in Lagos, Nigeria","authors":"Abdul-Azeez A. Anjorin ,&nbsp;Oluwaseyi S. Ashaka ,&nbsp;Joseph Eyedo ,&nbsp;Abdulrauf O. Abdulkareem ,&nbsp;Taofeeq A. Balogun ,&nbsp;Zainab B. Salami ,&nbsp;Kabiru O. Akinyemi","doi":"10.1016/j.jcvp.2025.100225","DOIUrl":"10.1016/j.jcvp.2025.100225","url":null,"abstract":"<div><h3>Background</h3><div>Human Bocavirus (HBoV) first described by Allander and colleagues in 2005 is one of the most common viral pathogens causing respiratory diseases. It is a single-stranded DNA virus from the Parvoviridae family that is associated with respiratory and gastrointestinal infections. The prevalence and impact of the HBoV in Lagos, Nigeria, particularly across all age groups, remain underexplored.</div></div><div><h3>Aim</h3><div>This study aimed to determine the prevalence of HBoV among individuals with respiratory symptoms and its association with disease in Lagos, Nigeria.</div></div><div><h3>Methods</h3><div>A hospital-based, cross-sectional study was conducted from December 2022 to May 2023 in Lagos. Nasopharyngeal swabs were collected from 400 participants presenting with respiratory symptoms across diverse age groups. The samples were analysed for HBoV DNA using real-time PCR. Demographic and clinical data were recorded, and statistical analysis was performed using SPSS.</div></div><div><h3>Results</h3><div>The overall prevalence of HBoV was 12.5 % (57/400), with a higher 24.6 % prevalence in participants aged 21–30 years than 8.4 % in those aged ≤10 years. The participants diagnosed with respiratory disease had a significantly greater 20.3 % prevalence of HBoV compared to 8.4 % without respiratory disease (χ²=11.69, <em>p</em> = 0.0006). Fever and runny nose were the most common symptoms among HBoV-positive participants, regardless of respiratory disease status.</div></div><div><h3>Conclusions</h3><div>HBoV is prevalent in Lagos and contributes significantly to respiratory illnesses across all age groups, with the highest burden observed in young adults. These findings underscore the need for further research on the clinical implications of HBoV and its potential for nosocomial transmission in healthcare settings.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 3","pages":"Article 100225"},"PeriodicalIF":1.6,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144550047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of recent SARS-CoV-2 infection on anti-spike protein immunoglobulin G II response after BNT162b2 vaccination","authors":"Daiki Tanno ,&nbsp;Yasuka Hara ,&nbsp;Yoshiyuki Sugaya ,&nbsp;Koji Okuaki ,&nbsp;Shuko Kobari ,&nbsp;Mitsuki Kitabatake ,&nbsp;Suguru Yui ,&nbsp;Tomoo Hidaka ,&nbsp;Masahiro Toyokawa ,&nbsp;Yumiko Kanari ,&nbsp;Kiwamu Nakamura ,&nbsp;Keiji Kanemitsu","doi":"10.1016/j.jcvp.2025.100224","DOIUrl":"10.1016/j.jcvp.2025.100224","url":null,"abstract":"<div><h3>Objectives</h3><div>Our hospital experienced a SARS-CoV-2 outbreak 3 months before staff vaccination was initiated. This study compared antibody responses to the first and second doses of BNT162b2 mRNA vaccine among staff with and without prior infection.</div></div><div><h3>Methods</h3><div>Serum anti-spike (S) protein immunoglobulin (anti-S) IgG, IgM, and anti-nuclear (N) protein IgG, IgM were measured 1 week before the first dose (baseline). Serum anti-S IgG II levels were sequentially measured at the baseline, 3 weeks after the first dose (immediately prior to the second dose), and 3 weeks and 6 months after the second dose to assess neutralization activity.</div></div><div><h3>Results</h3><div>Ten of the 83 staff had evidence of prior SARS-CoV-2 infection. The baseline anti-S IgG, IgG II, anti-N IgM, and anti-N IgG levels were significantly higher in those with prior infection. Three weeks after the first dose, the mean anti-S IgG II level was significantly higher in the prior-infection group (406.94 ± 163.44 AU/mL) than that in the uninfected group (40.43 ± 50.16 AU/mL; <em>p</em> &lt; 0.001). Three weeks after the second dose, the mean anti-S IgG II level was significantly lower than that after the first dose in the prior-infection group (240.28 ± 81.46 AU/mL; <em>p</em> = 0.007), and significantly higher in the uninfected group (341.45 ± 192.75 AU/mL; <em>p</em> &lt; 0.001). Six months after the second dose, the mean anti-S IgG II levels did not differ significantly between groups.</div></div><div><h3>Conclusions</h3><div>A single dose of BNT162b2 vaccine is sufficient to induce a peak anti-S IgG II response in recently infected individuals.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 3","pages":"Article 100224"},"PeriodicalIF":1.6,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144481545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics and outcomes of HBV-infected patients with HBsAg and anti- HBs coexistence","authors":"Nguyen Thi Cam Huong ,&nbsp;Pham Thi Hai Men ,&nbsp;Brian Thanh Do ,&nbsp;Hoa Pham Thi Le","doi":"10.1016/j.jcvp.2025.100220","DOIUrl":"10.1016/j.jcvp.2025.100220","url":null,"abstract":"<div><h3>Background</h3><div>The coexistence of HBsAg and anti-HBs is a unique detection in chronic HBV-infected patients. This serological status has not been reported in Vietnamese cases.</div></div><div><h3>Objectives</h3><div>description of HBV viral markers, activity of hepatitis, and progression of HBV-infected patients with HBsAg and anti-HBs coexistence over a six-month follow-up period and define related factors to HBsAg seroclearance.</div></div><div><h3>Method</h3><div>cross-sectional descriptive study with a six-month follow-up on patients who tested positive for HBsAg and anti-HBs simultaneously at the Liver Clinic nit, Hospital for Tropical Diseases, Vietnam, from 12/2018 to 12/2019.</div></div><div><h3>Result</h3><div>122 patients with coexistence of HBsAg and anti-HBs were included. 50.8 % were male, with median age of 42 (30-53). The median of ALT was 34 (24-66) U/L, 24.6 % had chronic hepatitis, 32 % had positive HBeAg, median of HBsAg was 1.76 ((-0.25) – (2.87)) log IU/mL, median of anti-HBs was 50 (24-99) mIU/mL, median of HBVDNA was 3.45 (1.46-6.55) log copies/mL. Eighty-four patients were confirmed chronic HBV infection with anti-HBs coexistence (68.9 %), 26.2 % loss HBsAg, and 6 cases (4.9 %) loss anti-HBs, as chronic HBV infection. Without chronic hepatitis, HBsAg &lt;100 S/CO, high anti-HBs, low HBsAg quantification lower 3 log IU/mL, HBeAg negative, HBV DNA lower 1.7 log copies/mL related to HBsAg seroclearance.</div></div><div><h3>Conclusion</h3><div>The coexistence of HBsAg and anti-HBs occurs in both HBeAg-negative and HBeAg-positive patients. Most cases had high viral load, and one-fourth of cases had chronic liver diseases. HBsAg loss occurred in 26.2 % of cases and related to chronic liver disease, low HBsAg, high anti-HBs, and low HBV DNA.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 3","pages":"Article 100220"},"PeriodicalIF":1.6,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144313444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}